Published: 9 April 2021


Medicines Assesment Advisory Committee

Agenda for the 110th meeting of the Medicines Assessment Advisory Committee to be held on 13 April 2021






Declaration of conflicts of interest


Applications for consent to distribute a new medicine under section 20 / 23 / 24 of the Medicines Act 1981 (referred by the Minister of Health under section 22(2))


COVID-19 Vaccine Janssen, 5×1010 virus particles (VP) in 0.5 mL suspension for injection (TT50-10862) Janssen-Cilag (New Zealand) Ltd

The product is a prescription medicine proposed for prevention of COVID-19 disease caused by SARS-CoV-2 in adults and adolescents from 18 years of age and older.

COVID-19 Vaccine Janssen is a monovalent vaccine composed of a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector, constructed to encode the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike (S) protein, stabilized in its prefusion conformation.

The application was received by Medsafe on 8 December 2020. The application has undergone one round of request for information.  The application is being considered for provisional consent under section 23 of the Medicines Act 1981 with proposed conditions.

The application is being referred to the Committee for independent advice as to whether the Minister of Health should grant provisional consent for the proposed indications. The Committee is also asked to consider the appropriateness of the conditions proposed for consent.


General business


Date of next meeting

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /